Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...

Children diagnosed with interstitial lung disease (ILD) are now more likely to survive into adulthood and may thus need care from adult ILD clinics for related impairments and complications. These ...

Patients with chronic obstructive pulmonary disease, interstitial lung disease and pulmonary hypertension experience improved ...

Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...

The following is a summary of “Diagnosis, screening, and follow-up of patients with familial interstitial lung disease: ...

The American Lung Association’s latest report on York County's air quality won't have anyone breathing a sigh of relief.

Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...

Gossamer Bio's Seralutinib shows promise for PAH and PH-ILD treatment. The main event comes with its topline results in Q4 ...

Watch this brave little girl deal with a very tough start to life after being diagnosed with an extremely rare lung disease.

Lung transplant recipients are highly susceptible to infection, the researchers noted, and P. aeruginosa is a leading cause ...

The median length of survival for individuals with ILD who completed pulmonary rehabilitation was 6.1 years vs 4.7 years in the control group. Pulmonary rehabilitation (PR) may improve survival at 5 ...